Woodline Partners LP Has $8.81 Million Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Woodline Partners LP grew its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 682.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,442,440 shares of the company's stock after buying an additional 3,002,622 shares during the period. Woodline Partners LP owned approximately 0.49% of ImmunityBio worth $8,813,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Stephens Inc. AR bought a new position in ImmunityBio during the 4th quarter worth $26,000. Cibc World Markets Corp bought a new position in shares of ImmunityBio in the fourth quarter worth $35,000. Maia Wealth LLC bought a new position in shares of ImmunityBio in the fourth quarter worth $37,000. Schechter Investment Advisors LLC bought a new position in shares of ImmunityBio in the fourth quarter worth $38,000. Finally, Ameriprise Financial Inc. bought a new position in shares of ImmunityBio in the fourth quarter worth $38,000. Institutional investors own 8.58% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Monday, May 12th. Piper Sandler upgraded ImmunityBio from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $4.25 to $5.00 in a research report on Tuesday, May 20th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Wednesday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ImmunityBio currently has an average rating of "Buy" and a consensus target price of $12.25.

ImmunityBio Trading Down 2.2%

ImmunityBio stock traded down $0.06 during midday trading on Wednesday, reaching $2.48. The company's stock had a trading volume of 1,528,380 shares, compared to its average volume of 7,218,066. ImmunityBio, Inc. has a 52 week low of $1.83 and a 52 week high of $7.63. The business has a 50-day moving average price of $2.62 and a 200-day moving average price of $3.15. The stock has a market cap of $2.18 billion, a PE ratio of -2.69 and a beta of 0.33.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The firm had revenue of $16.52 million during the quarter, compared to analysts' expectations of $17.50 million. As a group, research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.